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Background: A clinical trial of mometasone furoate/formoterol fumarate (MF/F) administered
via a metered-dose inhaler in subjects with moderate to very severe chronic obstructive
pulmonary disease (COPD) investigated the efficacy and safety of a fixed-dose combination
of MF/F.
Methods: This multicenter, double-blind, placebo-controlled trial had a 26-week treatment
period and a 26-week safety extension. Subjects (n = 1055; $40 years) were current or
ex-smokers randomized to twice-daily treatment with inhaled MF/F 400/10 µg, MF/F 200/10 µg,
MF 400 µg, F 10 µg, or placebo. The coprimary endpoints of the trial were mean changes from
baseline in forced expiratory volume in 1 second (FEV1) over 0–12 hours (AUC0–12 FEV1) with
MF/F versus MF, and in morning predose FEV1 with MF/F versus F. Key secondary endpoints
were quality of life (Saint George’s Respiratory Questionnaire [SGRQ]), symptom-free nights,
and partly stable COPD at 26 weeks, as well as time to first COPD exacerbation.
Results: Significant improvements in FEV1 AUC0–12 occurred at endpoint with MF/F 400/10
and MF/F 200/10 versus MF 400 (P # 0.007). Significant bronchodilation occurred in 5 minutes
with MF/F, and serial spirometry demonstrated sustained FEV1 improvements with MF/F over
the treatment period. Significant improvements in morning predose FEV1 occurred with both
MF/F doses, and these effects were further investigated by excluding results for subjects whose
morning FEV1 data were collected .2 days after the last dose of study treatment. Improvements
in SGRQ total scores surpassed the minimum clinically important difference of at least 4 units
with MF/F 400/10. MF/F 400/10 significantly reduced the time-to-first COPD exacerbation.
Similar proportions of subjects in all five treatment groups reported treatment-emergent adverse
events. Rates of pneumonia were low (#1.0%) across treatment groups.
Conclusion: MF/F 400/10 µg twice daily was shown to be an effective therapy for patients
with moderate to very severe COPD, and both MF/F 400/10 µg twice daily and MF/F 200/10 µg
twice daily were well tolerated.
Keywords: chronic obstructive pulmonary disease, FEV1, spirometry, exacerbation, inhaled
corticosteroid, bronchodilator
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Chronic obstructive pulmonary disease (COPD) is characterized by partially reversible
airway obstruction, dyspnea, productive cough, and progressive decline in overall
health.1,2 Although it may be preventable, COPD is debilitating for many patients
afflicted with the illness. The classic course of COPD is a gradual downward spiral
of lung function and activity level. As COPD worsens, patients are more likely
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to experience increasingly reduced functioning, acute
exacerbations of COPD,3 comorbid cardiovascular and metabolic disease, and possibly death.1,2,4
Moderate COPD has an estimated worldwide prevalence
of about 10%, based on data from 9425 patients in 12 cities
around the world.5 In recent years, COPD has surpassed
stroke as the third leading cause of death in the US. 6,7
Although COPD is a progressive disease, medications can
alleviate symptoms, reduce the number and severity of
exacerbations, and improve overall health status.1,2 In clinical
practice, bronchodilators relax airway smooth muscle and
improve lung emptying in patients with COPD.1 Inhaled
corticosteroids have also been found to provide some clinical improvements in patients with COPD due to their antiinflammatory effects.1 Although inhaled corticosteroids do
not appear to affect the accelerated long-term decline in
lung function typical of COPD,1 they reduce the number of
exacerbations and improve health status in patients with more
advanced disease,1 particularly when used concomitantly
with an inhaled long-acting beta-agonist (LABA).8 The additive clinical effects of inhaled corticosteroids when used with
LABAs8 may be due to synergistic effects via glucocorticoid
and β2-adrenergic receptor regulation.9,10
The benefits of using concomitant therapy with inhaled
corticosteroids plus inhaled LABA in the management of
patients with exacerbations and persistent symptoms (eg,
dyspnea, night-time awakenings) of COPD are cited by current COPD clinical guidelines.1,2,11 The Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines recommend addition of an inhaled corticosteroid to long-acting
bronchodilator therapy for patients with severe COPD (forced
expiratory volume in 1 second [FEV1] ,50% predicted) and
repeated exacerbations.2 In 2011 an official statement of
the American College of Physicians, American College of
Chest Physicians, American Thoracic Society, and European
Respiratory Society raised the FEV1 threshold from ,50%
to ,60% predicted for symptomatic patients with stable
COPD who may receive combination therapy.12
Currently, three inhaled corticosteroid-LABA combinations are available for the treatment of COPD, ie,
fluticasone propionate-salmeterol, budesonide-formoterol,
and beclomethasone-formoterol. Although investigations
of several inhaled corticosteroid-LABA combinations in
the treatment of COPD have been undertaken,13–21 use of
mometasone furoate with formoterol administered with a
metered-dose inhaler is a novel combination in this setting.
Individually, both mometasone furoate and formoterol have
been shown to be effective in the treatment of COPD,22–24
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and formoterol is approved for use in COPD. A fixed-dose
combination of MF/F has been shown to be effective for the
treatment of adolescents and adults with asthma.25–28 The
combination product of mometasone furoate/formoterol
fumarate (MF/F) offers both a potent inhaled corticosteroid29
with relatively low systemic bioavailability30 and a potent,
selective LABA with fast onset of action.31 These features
of combined MF/F have the potential to be of benefit to
patients with COPD. We undertook the present clinical trial,
a 26-week randomized, placebo-controlled efficacy and safety
study with a 26-week long-term safety extension, to evaluate
two therapeutic doses of MF/F in patients with moderate to
very severe COPD.

Materials and methods
Study design and treatments
This study was a randomized, placebo-controlled, parallelgroup, multicenter, double-blind, double-dummy study
(ClinicalTrials.gov identifier: NCT00383435) of MF/F in
adults with moderate to very severe COPD conducted in
131 centers located in South America, Asia, Africa, Europe,
and North America. The sponsor’s statistician produced a
computer-generated randomization schedule with treatment
codes in blocks using SAS. Randomization was stratified
according to the subject’s smoking status at the time of
randomization. Randomized treatment assignment was
provided to the investigative site by means of an interactive
voice response system at the time subjects were randomized.
To place all prospective participants on the same type of
treatment and to afford the same opportunity to demonstrate
improvement in lung function, the study included an openlabel run-in period in which long-acting bronchodilators
and corticosteroids were discontinued and substituted with
a short-acting β2-agonist (SABA)-anticholinergic fixed-dose
combination. Patients were randomly assigned for 26 weeks
(the treatment period) to one of five double-blind inhaled
treatments given twice daily, ie, MF/F 400/10 µg, MF/F
200/10 µg, MF 400 µg, F 10 µg, or placebo (Figure 1). For
each treatment, patients were instructed to take two inhalations delivered via metered-dose inhaler in order to receive
the full dose.
After 26 weeks of treatment, all patients randomized to
placebo were discontinued, while 75% of those receiving
active treatment were randomly selected to participate in a
26-week safety extension, continuing on the same treatment.
We refer to weeks 1 through 52 of this study (the treatment
period plus the safety extension) as the study period. All
randomized subjects had study visits at screening, baseline
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Screening period
open-label run-in
(SABA/short-acting
anticholinergic FDC)

Day-14
Screening
Baseline
(randomization)

26-week
double-blind treatment period

26-week double-blind
safety extension

MF/F MDI 400/10 mcg bid

MF/F MDI 400/10 mcg bida

MF/F MDI 200/10 mcg bid

MF/F MDI 200/10 mcg bida

MF MDI 400 mcg bid

MF MDI 400 mcg bida

F MDI 10 mcg bid

F MDI 10 mcg bida

Placebo

Figure 1 Study design schematic.
Note: Total doses were delivered after two inhalations twice daily of the following actuated doses: MF/F 200/5 µg, MF 100/5 µg, MF 200 µg, F 5 µg, or placebo. a75% of each
group were randomly selected to continue into the safety extension.
Abbreviations: bid, twice daily; F, formoterol; MDI, metered-dose inhaler; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.

(day 1), and weeks 1, 4, 13, and 26 in the treatment period.
Subjects in the safety extension had additional visits at weeks
39 and 52.
Written informed consent was obtained from each patient
prior to any study-related activity. Prior to study initiation
at each study site, the clinical study protocol and the written
informed consent form were reviewed and approved by an
institutional review board/independent ethics committee.

Patients
We recruited adult males and females who were current or
former smokers with a smoking history of $10 pack-years.
Eligible patients were at least 40 years of age and had received
a diagnosis of moderate to very severe COPD, based on a
pre-bronchodilator FEV1/forced vital capacity (FVC) ratio
of #0.70. They must have had symptoms of COPD (chronic
cough and sputum production not attributable to another
disease process) for at least 24 months, and a post-bronchodilator FEV1 #60% predicted normal and $25% predicted
normal at screening. Females with childbearing potential
were required to use a medically acceptable form of birth
control. We excluded patients who experienced an increase
in absolute volume of $400 mL at the screening visit or prior
to the baseline visit within 30 minutes after administration of
four inhalations of albuterol/salbutamol (total dose of 360 to
400 µg), or nebulized 2.5 mg albuterol-salbutamol. Patients
requiring long-term administration of oxygen (.15 hours per
day) or who experienced an exacerbation of COPD requiring
medical intervention within four weeks prior to randomization, β-blocking agents, or treatment with additional excluded
medication (other than SABA-short-acting anticholinergic
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to be used as rescue medication) were not enrolled. Patients
with a history of significant medical illness or a disorder that
might interfere with the study or that required treatment that
might interfere with the study were also excluded. Other
reasons for exclusion included pregnancy or breast-feeding,
a diagnosis of asthma, lung cancer, or alpha-1-antitrypsin
deficiency, or a history of lobectomy, pneumonectomy, lung
volume reduction surgery, cataract extractions in both eyes,
or other significant ocular problems (glaucoma, trauma,
opacification).

Outcome measurements and
assessments
Coprimary endpoints

In order to measure the contribution of each drug treatment
to the combination, the study used two coprimary efficacy
endpoints. The first coprimary endpoint was the mean change
from baseline in FEV1 area under the curve from 0 to 12 hours
postdose (AUC0–12 h) at the week 13 endpoint (to assess
the contribution of F 10 to the combination). The second
coprimary endpoint was the mean change from baseline in
morning predose FEV1 at the week 13 endpoint (to assess
the contribution of MF to the combination).

Key secondary endpoints
The study had four key secondary endpoints assessed for
MF/F 400/10 and MF/F 200/10 at the end of the treatment
period, ie, change in health status as assessed according to
total scores on the St George’s Respiratory Questionnaire
(SGRQ),32 change in symptom-free nights, time-to-first mild,
moderate, or severe COPD exacerbation, and the proportion
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of patients with partly stable COPD. The SGRQ consists of
three component scores (symptoms, activity, impact) and a
total score, each of which ranges from 0 to 100. The better
SGRQ scores have a lower numeric value. The minimum
clinically important difference (MCID) for SGRQ scores is
defined as a 4-point difference from baseline or placebo.33
A symptom-free night was defined as a combined score of
0 upon awakening, prior to the use of study drug or rescue
medication, across three domains, ie, wheezing, cough, and
difficulty breathing. Partly stable COPD was defined as a
composite measure of the following outcomes: no use of
oral steroid rescue medication; no morning or afternoon
COPD weekly average symptom score .2 during at least
7 of 8 weeks; no moderate or severe COPD exacerbations;
no unscheduled visits due to COPD worsening; and no study
discontinuation due to treatment failure or a treatment-related
adverse event.

Safety and e-diary assessments
Safety assessments at each study visit included monitoring of treatment-emergent adverse events, vital signs,
oropharyngeal changes, and forearm bruising. Adverse
events may have included the onset of new illness and
the exacerbation of pre-existing conditions (eg, COPD).
As directed by the study protocol, a medically qualified investigator at each site assessed the relationship of
adverse events to study treatment, while treatment was
blinded, as being unlikely, possibly, or probably related
to treatment. Laboratory assessments, electrocardiography, and ophthalmologic examinations were conducted
at screening and at the final visit. Chylack Incorporated
(Duxbury, MA) provided guidance for ocular examinations
and online training to ophthalmologists for Lens Opacities
Classification System Version III (LOCS III) certification.
Measurements of bone mineral density and 24-hour plasma
cortisol were conducted at selected centers. Dual energy
x-ray absorptiometry scans of the lumbar spine, left total
femur, and femoral neck were obtained for a subgroup
of subjects at selected centers. CCBR-Synarc (Portland,
OR) provided centralized analysis of the scans, project
management related to dual energy x-ray absorptiometry,
and instrument quality control.
Each patient was given an e-diary (CareFusion Germany,
234 GmBH Services, Hoechberg, Germany) with a built-in
spirometer to capture peak expiratory flow and a self-contained
device to record information about medication use, nocturnal
awakenings, COPD symptoms, and disease stability. COPD
stability was evaluated with a 5-point or 6-point scale (0 = best,
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4–5 = worst) measuring breathlessness, mucus production,
chest tightness, cough, interference with personal care, and
interference with outdoor activities.

Statistical analysis
The first coprimary efficacy endpoint (FEV 1 AUC0–12)
compared MF/F 400/10 versus MF 400, MF/F 400/10
versus placebo, and F 10 versus placebo. All of these comparisons had to be statistically significant at this dose level
of MF/F to assess successfully the contribution of F 10 to
the combination. The second coprimary efficacy endpoint
(morning predose FEV1) compared MF/F 400/10 versus
F 10, MF/F 400/10 versus placebo, and MF 400 versus
placebo. All of these comparisons had to be statistically
significant at this dose level of MF/F to assess successfully
the contribution of MF 400 to the combination.
The target sample size was 1000 subjects (200 subjects
per treatment group). This sample size was considered
sufficient to detect a difference of 1.2 L × hour between
MF/F 400/10 and MF 400 in change from baseline FEV1
AUC0–12 h with 91% power and a two-sided alpha level of
5% significance, assuming a pooled standard deviation of
3.6 L × hour. A 1.2 L × hour AUC converts to an average
difference of 100 mL in FEV1 across 12 hours. A difference of this magnitude is considered clinically meaningful in subjects with this severity of COPD. For a morning
predose FEV1 at the week 13 endpoint, the contribution
of the MF 400 component was expected to be 80 mL for
a target treatment difference of 160 mL between MF/F
400/10 and placebo. This treatment difference could be
detected at 93% power with a two-sided alpha level of
4.9%, assuming a pooled standard deviation of 230 mL.
The alpha level was adjusted to allow for a nominal penalty
of 0.1%. The coprimary comparisons had to be statistically
significant to proceed with additional efficacy analyses. The
contribution of MF to the MF/F combination was evaluated
by analyzing results in subjects whose morning predose
FEV1 measurements were obtained in the protocol-defined
time period, using values considered as actual trough FEV1
values. In a second analysis performed post database lock,
FEV1 evaluations for each subject performed $2 days
after the last dose of treatment were excluded, and the
week 13 morning predose FEV1 endpoint was recalculated
using the last remaining evaluation as specified in the
study protocol.
To assess the coprimary endpoints, an analysis of
covariance extracting sources of variation due to treatment,
country, smoking status, and baseline as a covariate, was
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used. Pairwise comparisons were based on least square means
from the model. An analysis of variance extracting sources
of variation due to treatment, country, and smoking status,
was performed also as a confirmatory analysis for these
treatment comparisons.
Following testing of the coprimary endpoints at a given
dose level, the key secondary endpoints were analyzed
sequentially versus placebo. The first two key secondary
variables (change from baseline in SGRQ total score and
proportion of COPD symptom-free nights) were assessed
using the same analysis of covariance as specified for the
coprimary efficacy variables. The third key secondary variable (proportion of subjects with partly stable COPD) was
analyzed using the Cochran-Mantel-Haenszel test controlling for smoking status. For the fourth key secondary variable (time-to-first mild, moderate, or very severe COPD
exacerbation) the log-rank test for equality of survival curves
was used. Kaplan-Meier curves were used to display these
treatment responses. In addition, the effect of smoking status
on the survival curves was examined. Assessments were
repeated for MF/F 200/10.

Results
Subject disposition and demographics
Of 2313 subjects recruited, 1059 underwent randomization;
however, four randomized subjects who had protocol
violations were excluded from analyses, leaving 1055
randomized patients, two of whom did not receive the study
drug. A total of 840 patients (80%) completed the treatment
period, while 215 subjects (20%) discontinued from the
study early, primarily for reasons unrelated to study treatment
(Table 1). Treatment groups were well balanced regarding

baseline demographic characteristics with respect to age,
race, and sex (Table 2). The treatment groups had similar
smoking histories.
A total of 529 patients on active treatment continued
into the safety extension, 472 of whom (89%) completed the
26-week double-blind extension period. A total of 57 patients
(11%) did not complete the safety extension. Of these patients,
17 (3%) discontinued due to adverse events, and 16 (3%)
discontinued for reasons unrelated to study treatment.

Coprimary efficacy variables
Treatment with MF/F resulted in significant improvements
in FEV1 which demonstrated the superiority of the combination versus the individual components. The contribution of
F 10 to the MF/F 400/10 combination was demonstrated at
the week 13 endpoint by the statistically significant effect
of MF/F 400/10 over MF 400 in FEV1 AUC0–12 h (109 mL;
Table 3). An overall effect size of 163 mL was observed for
MF/F 400/10 over placebo at this endpoint (P , 0.001). In
addition, a statistically significant advantage of F 10 monotherapy over placebo was demonstrated, with an improvement
of 74 mL (P = 0.003, Figure 2).
A comparison of MF/F 200/10 with MF 400 monotherapy at the week 13 endpoint also demonstrated the
statistically significant effect of F 10, with an improvement
of 69 mL (P = 0.007). The significant improvement of FEV1
AUC0–12 h with MF/F 400/10 versus F 10 (89 mL, P , 0.001)
confirms the contribution of MF to the combination. The
improvement of MF/F 200/10 over F 10 was shown to be
49 mL at this endpoint (P = 0.055). When compared with
the MF 400 arm, MF/F 400/10 showed a 109 mL improvement at the week 13 endpoint and MF/F 200/10 showed a

Table 1 Disposition of patients following randomized treatment assignment: number (%) of patients during the treatment period
Subject disposition, n (%)

MF/F 200/10 μg
bid

MF/F 400/10 μg
bid

MF 400 μg
bid

F 10 μg
bid

Placebo

Total

Randomized
Discontinued treatment period
Adverse event
Treatment failure
Lost to follow-up
 Subject did not wish to continue
for reasons unrelated to treatment
 Subject did not wish to continue
for reasons related to treatment
Noncompliance with protocol
Did not meet protocol eligibility
Administrative
Completed treatment period

207
38 (18)
2 (1)
2 (1)
3 (1)
12 (6)

217
41 (19)
10 (5)
3 (1)
3 (1)
7 (3)

210
46 (22)
8 (4)
3 (1)
1 (,1)
14 (7)

209
37 (18)
6 (3)
5 (2)
2 (1)
10 (5)

212
53 (25)
8 (4)
8 (4)
2 (1)
17 (8)

1055
215 (20)
34 (3)
21 (2)
11 (1)
60 (6)

3 (1)

2 (1)

7 (3)

3 (1)

7 (3)

22 (2)

5 (2)
8 (4)
3 (1)
169 (82)

1 (,1)
10 (5)
5 (2)
176 (81)

3 (1)
9 (4)
1 (,1)
164 (78)

5 (2)
5 (2)
1 (,1)
172 (82)

4 (2)
6 (3)
1 (,1)
159 (75)

18 (2)
38 (4)
11 (1)
840 (80)

Abbreviations: bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.
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Table 2 Summary of demographic data and baseline characteristics (all randomized subjects)
Characteristics

MF/F 200/10 μg bid
(n = 207)

MF/F 400/10 μg bid
(n = 217)

MF 400 μg bid
(n = 210)

F 10 μg bid
(n = 209)

Placebo
(n = 212)

46 (22)
161 (78)
60.9 (8.1)
72.42 (16.46)

46 (21)
171 (79)
59.7 (9.1)
72.86 (19.05)

46 (22)
164 (78)
59.8 (8.9)
73.46 (18.31)

57 (27)
152 (73)
59.6 (8.5)
74.41 (17.37)

42 (20)
170 (80)
58.8 (8.7)
73.95 (18.82)

158 (76)
1 (,1)
44 (21)
4 (2)

167 (77)
0
44 (20)
6 (3)

159 (76)
2 (1)
42 (20)
7 (3)

161 (77)
2 (1)
40 (19)
6 (3)

155 (73)
3 (1)
46 (22)
8 (4)

89 (43)
118 (57)
41.74 (43.39)

99 (46)
118 (54)
39.73 (28.43)

92 (44)
117 (56)
40.03 (29.28)

92 (44)
117 (56)
40.34 (28.97)

97 (46)
115 (54)
40.29 (37.22)

Sex, n (%)
Female
Male
Age, mean, years (SD)
Weight, mean kg (SD)
Race, n (%)
White
Black or African American
Asian
Multiracial
Smoking status, n (%)
Current smokers
Ex-smokers
Smoking history, mean pack-years (SD)

Abbreviations: bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination; SD, standard deviation.

69 mL improvement. Also at the week 13 endpoint, effect
sizes of 123 mL for MF/F 200/10 and 163 mL for MF/F
400/10 over placebo were significant (P , 0.001) and demonstrated the overall benefit of MF/F. The additional benefit
of 40 mL in the MF/F 400/10 group demonstrated a degree
of dose-response compared with the MF/F 200/10 group.
Serial spirometric assessment of FEV1 at the beginning
(day 1) and end (week 26) of treatment identified the rapid
onset and sustained duration of bronchodilator effects with
MF/F (Figure 3).
Substantial evidence indicated the contribution of the
MF component to the combination, as demonstrated by the
significant effects on morning predose FEV1 for MF/F 400/10
and MF/F 200/10 over F 10 alone (111 mL and 58 mL,
respectively). An overall effect size of 128 mL was observed
for MF/F 400/10 over placebo (P , 0.001). Although MF/F
400/10 demonstrated more efficacy than MF/F 200/10
(P = 0.045), both doses of MF/F demonstrated efficacy
in this endpoint. Some subjects had FEV1 measurements
long after they had stopped taking study treatment. In the
second analysis of morning predose FEV1 which excluded
subjects in whom FEV1 was measured .2 days after their
last dose of treatment, a significant difference of 110 mL
between MF/F 400/10 and F 10 (P , 0.001) confirmed the
contribution of MF to the combination. Predose FEV1 data,
collected from the daily diary recorded at the subject’s home
support the effect observed from spirometry measured at the
clinic visits.

Key secondary efficacy variables
A 4-point increase over that of placebo (as well as over
baseline) is considered the MCID for the SGRQ. MF/F
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400/10 exceeded the MCID of 4 points compared with
p lacebo, with a significant effect size of 4.56 points
(P = 0.002) for SGRQ total score at the week 26 endpoint.
In addition, a clinically meaningful difference of 4.12
points was observed for the MF 400 component, achieving
significance compared with placebo (P = 0.006), while the
F 10 component achieved significance with an effect size
of 3.31 points compared with placebo (P = 0.026). Statistically significant improvements in SGRQ total score for
MF/F 400/10 over placebo were demonstrated at weeks 4,
13, and 26 (P # 0.040). MF/F 200/10 did not achieve the
MCID, with a 2.82-point reduction compared with placebo
(Figure 4).
The proportion of COPD symptom-free nights was
improved with MF/F 400/10 (0.15) nights versus placebo
(0.06) nights, achieving statistical significance (P = 0.001)
over the 26-week treatment period. However, there was no
treatment difference between MF/F 400/10 and placebo in
the proportion of subjects with partly stable COPD at the
26-week endpoint (last 8 weeks on treatment for each subject). Percentages ranged from 37.8% to 45.9% across the
treatment groups.
MF/F 400/10 demonstrated a significant improvement
over F 10 (P = 0.015) for the time-to-first COPD exacerbation (Figure 5). Subjects treated with MF/F 400/10 had the
lowest rate of mild, moderate, or severe COPD exacerbations
across treatments (25.8%), the relative reduction over placebo
(20.6%) being nominally marginally significant (P = 0.079).
MF/F 200/10 showed no reduction in mild, moderate, or
severe exacerbations over placebo, and a 12.1% (P = 0.394)
relative reduction in moderate or severe exacerbations.
Since moderate or severe exacerbations are considered more
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70∫

68∫
77∫
65

56∫

57∫
54

115*,†
137*,†

206
190
182
207
163
207

134*,†,∫
126*,†
120*,†
110*,†

1227
207

Baseline
Change from BL
Day 1
Week 1
Week 13
Week 13 EPb
Week 26
Week 26 EPb
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69 mL
P = 0.007

200
180

166

109 mL
P < 0.001

160

FEV1 AUC (mL)

Notes: aRaw means; blast post-baseline non-missing result through the 13-week or 26-week evaluation carried forward. The baseline FEV1 was the average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour,
immediately prior to dosing) at the baseline visit. *P , 0.001 versus placebo; †P , 0.05 versus MF 400; ‡P , 0.001 versus MF 400; ¶P , 0.05 versus F 10; ∫P # 0.05 versus placebo.
Abbreviations: AUC, area under curve; bid, twice daily; BL, baseline; EP, endpoint; F, formoterol; FEV1, forced expiratory volume in 1 second; LS, least squares; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixeddose combination.

-0.7%
-0.2%

1.3%

-0.5%
0%
0.6%

-20
0
3
11
0

12

100*
100*
29

205
186
175
207
155
207
12.3%
15.2%
15.4%
14.8%
14.0%
13.2%
138*,‡,∫
164*,‡,∫
173*,‡,¶
166*,‡,¶
170*,‡,¶
154*,‡
10.8%
12.6%
12.2%
11.5%
9.4%
9.3%

213
198
183
214
167
214

1186
214

Mean
% changea
LS
mean

56∫
55

1255
207

4.0%
6.1%
6.1%
6.6%
6.0%
6.6%

207
199
183
208
156
208

208

1252

8.9%
9.4%
6.7%
7.4%
5.2%
6.1%

203
183
167
207
138
207

1227
207

LS
mean
n
LS
mean
n
LS
mean
n
Mean
% changea
n

LS
mean

MF/F 400/10 μg bid

n

MF/F 200/10 μg bid
P # 0.001

Table 3 Change from baseline in standardized FEV1 AUC0–12 h (mL)

MF 400 μg bid

Mean
% changea

F 10 μg bid

Mean
% changea

Placebo

Mean
% changea

Mometasone-formoterol in COPD

140

126

120
100
77

80

74 mL
P = 0.003

57

60
40
20

3

0
MF/F MDI
200/10

MF/F MDI
400/10

MF MDI
400

F MDI 10

Placebo

Figure 2 FEV1 AUC0–12 h week 13 last observation carried forward results (all
randomized subjects).
Abbreviations: AUC, area under curve; FEV1, forced expiratory volume in 1
second; F, formoterol; MDI, metered-dose inhaler; MF, mometasone furoate; MF/F,
mometasone furoate/formoterol fixed-dose combination.

clinically important, an additional analysis excluding mild
exacerbations was performed. This analysis showed that
subjects on placebo had a higher rate of moderate or severe
COPD exacerbations (16.5%) than those on MF/F 400/10
(8.8%; P = 0.009), with a relative reduction for the MF/F
400/10 combination of 46.7% over placebo.

Safety

Treatment-emergent adverse events
Treatment with MF/F 400/10 and MF/F 200/10 was well
tolerated. During the 26-week treatment period, the percentage of subjects reporting treatment-emergent adverse events
was similar between treatment groups, ranging from 26.3% in
the MF/F 400/10 group to 33.5% in the F 10 group (Table 4).
The most commonly reported treatment-emergent adverse
events were headache, upper respiratory tract infection,
cough, COPD, and hypertension (Table 5). The percentages
of subjects reporting pneumonia during the 26-week treatment period were low, ranging from 0% to 1.0% across all
treatment groups.
During the study period (week 1 through week 52), the
incidence of treatment-emergent adverse events in the active
treatment groups ranged from 35.9% for MF/F 200/10 to
42.1% for F 10 (Table 4). The most commonly reported treatment-emergent adverse events among the four active-treatment
groups were COPD, headache, nasopharyngitis, upper respiratory tract infection, and hypertension (Table 6).
During the treatment period, 68 subjects reported serious
treatment-emergent adverse events. The most frequently
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Mean change from baseline (%)

A
20

20

16

16

12

12

8

8

4

4

0

0

−4

0

5
15 30
Time (minutes)

1

2

3

MF/F 400/10 µg bid (n = 216)
MF/F 200/10 µg bid (n = 208)

4
6
8
10
Time (hours)

11

12

−4

0

MF 400 µg bid (n = 209)
F 10 µg bid (n = 209)
Placebo (n = 208)

5
15 30
Time (minutes)

1

2

3

MF/F 400/10 µg bid (n = 178)
MF/F 200/10 µg bid (n = 177)

4
6
8
Time (hours)

10

11

12

MF 400 µg bid (n = 168)
F 10 µg bid (n = 175)
Placebo (n = 165)

Figure 3 Serial FEV1 postdose at day 1 (A) and week 26 (B).
Notes: Significantly greater increases in FEV1 occurred with MF/F 400/10 versus MF 400 at all time points on day 1 (P # 0.009) and week 26 (P # 0.042). Significant increases
in FEV1 with MF/F 200/10 versus MF 400 occurred through 10 hours on day 1 (P # 0.015) and 4 hours on week 26 (P # 0.026). Compared with F 10, MF/F 400/10 had
significantly greater increases in FEV1 at all time points in week 26 (P , 0.05), whereas MF/F 200/10 had significantly greater increases than F 10 at hours 8, 10, and 12
postdose in week 26 (P # 0.025).
Abbreviations: bid, twice daily; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose
combination.

reported adverse events were oral candidiasis, cough, and
COPD. There were 16 all-cause mortality events across treatment groups during the 52 weeks of the study. Eleven of the
deaths occurred during the treatment period (week 1 through
week 26) and five occurred during the safety extension
(week 27 through week 52). There were no abnormal, clinically relevant trends in laboratory values, vital signs, bone
mineral density loss, plasma cortisol levels, ocular changes,
or new findings of oral candidiasis or forearm bruising.
MF/F 200/10 MF/F 400/10

Thirteen fractures were reported over the study, comprising
one in the MF/F 400/10 group (vertebral), three in the MF/F
200/10 group (two lower limb, one wrist), three in the MF
400 group (one radius, one facial bone, one rib), five in the
F 10 group (one each at the radius, ulna, and wrist, and two
rib), and one in the placebo group (foot).
Rates of pneumonia were low across all treatment groups,
with no notable differences between the treatment period
and study period or between the MF-containing and non
MF 400

F10

Placebo

0

Change from baseline in
total SGRQ score, LS mean

−1
−2
−3
−4
−5
−6
−7

−4.12, P = 0.006

−8
−9

−4.56, P = 0.002

−10
Figure 4 St George’s Respiratory Questionnaire total score change from baseline at week 26 endpoint.
Note: Treatment with MF/F 400/10 achieved a statistically significant difference from placebo, which satisfied this key secondary endpoint and surpassed the MCID of 4.0.
Abbreviations: F, formoterol; LS, least squares; MCID, minimum clinically important difference; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixeddose combination; SGRQ, St George’s Respiratory Questionnaire.
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Probability of no COPD exacerbation
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MF/F 200/10
F 10
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Figure 5 Time-to-first mild, moderate or severe COPD exacerbation over the 26-week treatment period: Kaplan-Meier survival curves by treatment (all randomized subjects).
Abbreviations: COPD, chronic obstructive pulmonary disease; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.

MF-containing treatment groups. During the 26-week treatment period, six subjects (0.6%) receiving active treatment
or placebo reported pneumonia, and over the 52-week study
period, 11 subjects (1.3%) across the active treatment groups
reported pneumonia (Table 4). Most cases of pneumonia were
of moderate severity.

Treatment-related adverse events
During the study, 62 of 843 subjects (7.4%) across the active
treatment groups reported an adverse event considered by
the investigator to be treatment-related. The most common
adverse events considered possibly treatment-related were
oral candidiasis, cough, and lenticular opacities. Only one case
of pneumonia (in the placebo group) and one fracture (in the
F 10 group) were considered possibly treatment-related.

Systemic and ocular effects
No clinically meaningful electrocardiographic changes were
observed during the study period. Study treatments had minimal effects on the hypothalamic-pituitary-adrenal axis and
bone mineral density, as measured at selected centers over
the study period. Baseline 24-hour plasma cortisol levels
ranged from 190.1 to 220.8 µg/dL ⋅ hour, and small, insignificant decreases in plasma cortisol were seen across all active
International Journal of COPD 2012:7

treatment groups at week 26 and week 52. For bone mineral
density in the lumbar spine, the region of greatest interest,
decreases in bone mineral density were ,1% for the MF/F
200/10 and MF 400 groups. The greatest loss of bone mineral
density at lumbar spine was −0.6% in the MF 400 group at
week 26. None of the between-treatment comparisons were
statistically significant at weeks 26 or 52. Only five subjects
had a bone mineral density loss at the lumbar spine .6%
during the study period, comprising two subjects in the MF/F
200/10 group and three subjects in the MF 400 group.
Ophthalmologic examinations found that between 4.1%
(MF/F 400/10) and 7.1% (MF 400) of subjects had LOCS
III increases of $1 unit over the 52-week study period. One
subject each in the MF/F 200/10 and MF/F 400/10 groups,
two MF 400 subjects, and one placebo subject reported cataracts and were discontinued from the study, as per protocol.
Additionally, intraocular pressure $22 mmHg was reported
for four subjects (three on MF/F 400/10 and one on F 10)
at week 26 and three subjects (one each on MF/F 200/10,
MF 400, and F 10) at week 52.

Discussion
This clinical study demonstrated efficacy and safety for
the combination of inhaled MF and F in the treatment of
submit your manuscript | www.dovepress.com
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Table 4 Summary of treatment-emergent adverse events
Number of subjects (%)
MF/F 200/10 μg bid
(n = 207)
Treatment period (weeks 1–26)
Any AE
62 (30.0)
Severe or life-threatening AEs
6 (2.9)
Life-threatening AEs
0
Serious AEs
8 (3.9)
Discontinuations due to AEs
2 (1.0)
Deaths
1 (0.4)
Pneumonia
1 (0.5)
Treatment-related AEs
9 (4.3)
Treatment period + safety extension (weeks 1–52)
Any AE
78 (37.7)
Severe or life-threatening AEs
7 (3.4)
Life-threatening AEs
1 (0.5)
Serious AEs
13 (6.3)
Discontinuations due to AEs
4 (1.9)
Deaths
1 (0.4)
Pneumonia
1 (0.5)
Treatment-related AEs
12 (5.8)

MF/F 400/10 μg bid
(n = 217)

MF 400 μg bid
(n = 210)

F 10 μg bid
(n = 209)

Placebo bid
(n = 212)

57 (26.3)
9 (4.1)
4 (1.8)
16 (7.4)
10 (4.6)
1 (0.4)
2 (0.9)
13 (6.0)

62 (29.5)
15 (7.1)
4 (1.9)
15 (7.1)
9 (4.3)
3 (1.4)
0
12 (5.7)

70 (33.5)
16 (7.7)
4 (1.9)
17 (8.1)
6 (2.9)
3 (1.4)
2 (1.0)
15 (7.2)

67 (31.6)
12 (5.7)
3 (1.4)
12 (5.7)
8 (3.8)
1 (0.4)
1 (0.5)
10 (4.7)

78 (35.9)
21 (9.7)
6 (2.8)
29 (13.4)
14 (6.5)
3 (1.3)
4 (1.8)
18 (8.3)

86 (41.07)
19 (9.0)
4 (1.9)
22 (10.5)
13 (6.2)
3 (1.4)
2 (1.0)
15 (7.1)

88 (42.1)
24 (11.5)
6 (2.9)
29 (13.9)
11 (5.3)
8 (3.8)
2 (1.9)
17 (8.1)

Abbreviations: AE, adverse event; bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.

subjects with moderate to very severe COPD and showed
that each component contributes to the combination. The
F component demonstrated a significant and clinically
meaningful contribution to the combination (109 mL)
based on the comparison of MF/F 400/10 with MF 400 in
change from baseline in the FEV1 AUC0–12 h at the week
13 endpoint. The MF component also demonstrated a significant contribution to the combination (111 mL) based
on the comparison of MF/F 400/10 with F 10 in morning
predose (trough) FEV1 at the week 13 endpoint. The results
are significant and document a rapid onset of action of
MF/F within 5 minutes, with significant bronchodilator
effects that are sustained over the 12-hour dosing interval.
In addition, the study demonstrates that both the rapidity

of onset and magnitude of bronchodilation are maintained
to the end of the 26-week treatment period without any
evidence of tachyphylaxis. The study had a 12-hour period
for serial spirometry, which was substantially longer
than the 1-hour or 2-hour serial spirometry assessments
in pivotal trials of other inhaled corticosteroids-LABA
fixed-dose combinations,15,17,18 although a recent trial of
budesonide-F included serial spirometry data that extended
for 12 hours.34
A dose-related response for lung function was also
observed, with MF/F 400/10 showing an additional benefit of 53 mL versus MF/F 200/10, when compared with
F 10. At the week 13 endpoint, the MF contribution is
also demonstrated by the 40 mL change in FEV1 AUC0–12 h

Table 5 Summary of treatment-emergent adverse events $2% incidence (all randomized subjects) during the treatment period
Adverse events, n (%)

MF/F 200/10 μg bid
(n = 207)

MF/F 400/10 μg bid
(n = 217)

MF 400 μg bid
(n = 210)

F 10 μg bid
(n = 209)

Placebo
(n = 212)

Patients reporting any adverse event
Chest pain
Influenza
Oral candidiasis
Upper respiratory tract infection
Headache
Chronic obstructive pulmonary diseasea
Cough
Hypertension

62 (30.0)
1 (0.5)
2 (1.0)
1 (0.5)
3 (1.4)
8 (3.9)
3 (1.4)
3 (1.4)
6 (2.9)

57 (26.3)
0
1 (0.5)
3 (1.4)
6 (2.8)
5 (2.3)
5 (2.3)
3 (1.4)
2 (0.9)

62 (29.5)
1 (0.5)
3 (1.4)
5 (2.4)
4 (1.9)
4 (1.9)
5 (2.4)
3 (1.4)
2 (1.0)

70 (33.5)
5 (2.4)
5 (2.4)
0
1 (0.5)
8 (3.8)
6 (2.9)
6 (2.9)
3 (1.4)

67 (31.6)
4 (1.9)
2 (0.9)
2 (0.9)
5 (2.4)
8 (3.8)
7 (3.3)
3 (1.4)
5 (2.4)

Note: aIf COPD exacerbation met criteria for a severe AE (eg, was life-threatening, required hospitalization or prolonged hospitalization) it was recorded as an AE.
Abbreviations: bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.

52

submit your manuscript | www.dovepress.com

Dovepress

International Journal of COPD 2012:7

Dovepress

Mometasone-formoterol in COPD

Table 6 Summary of treatment-emergent adverse events $2% incidence (all randomized subjects) during the study period
Adverse events, n (%)

MF/F 200/10 μg bid
(n = 207)

MF/F 400/10 μg bid
(n = 217)

MF 400 μg bid
(n = 210)

F 10 μg bid
(n = 209)

Subjects reporting any adverse event
Chest pain
Influenza
Nasopharyngitis
Oral candidiasis
Respiratory tract infection
Upper respiratory tract infection
Back pain
Headache
Chronic obstructive pulmonary disease*
Cough
Hypertension

78 (37.7)
1 (0.5)
2 (1.0)
4 (1.9)
1 (0.5)
3 (1.4)
3 (1.4)
3 (1.4)
8 (3.9)
4 (1.9)
4 (1.9)
9 (4.3)

78 (35.9)
0
2 (0.9)
7 (3.2)
4 (1.8)
2 (0.9)
8 (3.7)
1 (0.5)
8 (3.7)
13 (6.0)
4 (1.8)
4 (1.8)

86 (41.0)
1 (0.5)
5 (2.4)
7 (3.3)
5 (2.4)
5 (2.4)
5 (2.4)
2 (1.0)
6 (2.9)
6 (2.9)
4 (1.9)
3 (1.4)

88 (42.1)
5 (2.4)
6 (2.9)
3 (1.4)
0
3 (1.4)
4 (1.9)
5 (2.4)
8 (3.8)
10 (4.8)
6 (2.9)
3 (1.4)

Note: *If COPD exacerbation met criteria for a severe adverse event (eg, was life-threatening, required hospitalization or prolonged hospitalization) it was recorded as an
adverse event.
Abbreviations: bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.

between the MF/F 200/10 and MF/F 400/10 combinations,
since the dose of the F component remains constant and
only the dose of the MF component is increased. The
effect seen in both FEV1 AUC0–12 h and morning predose
FEV1 shows the additive effects of the inhaled corticosteroid and LABA components of the combination. At the
week 13 endpoint, MF 400 showed a 27 mL improvement
from baseline in morning predose FEV1 and F 10 had no
improvement at the week 13 endpoint; however, MF/F
400/10 had a 111 mL improvement at the week 13 endpoint.
In FEV1 AUC0–12 h, MF 400 had a 57 mL improvement from
baseline and F 10 had a 77 mL improvement, whereas
MF/F 400/10 had a 166 mL improvement. These findings
are consistent with both preclinical and clinical reports
of each component enhancing the effect of the other. The
comparatively greater efficacy of MF/F 400/10 over MF/F
200/10 on lung function supports a dose-response effect
of the MF component.
This study demonstrated a clinically relevant improvement in health-related quality of life compared with
placebo for both the week 13 and week 26 endpoints, which
is a clinically significant outcome rarely demonstrated in
COPD trials. The MF/F 400/10 arm also demonstrated a
significant improvement over placebo in the second key
secondary endpoint of proportion of COPD symptom-free
nights.
Comparison of the MF/F 400/10 combination with
placebo showed a nominally significant relative reduction
of 20.6% in the rate of mild, moderate, or severe exacerbations (P = 0.079). However, the relative reduction of 46.7%
in moderate to severe exacerbations for the MF/F 400/10
combination compared with placebo is significant (P = 0.009)

International Journal of COPD 2012:7

and clinically important. Statistically significant reductions
were also shown for MF/F 400/10 compared with MF and
F alone, despite a treatment period of only 6 months. Historically, it has been difficult to show significant effects
on exacerbations with pharmacotherapy within this short
timeframe.
Overall, treatment with MF/F was well tolerated in this
study. The study demonstrated a low rate of pneumonia in
all groups, including subjects who received treatments containing an inhaled corticosteroid. In contrast with findings
of a meta-analysis reporting a dose-related increase in the
risk of pneumonia with inhaled corticosteroid-containing
treatments (inhaled corticosteroid monotherapy and inhaled
corticosteroid-LABA combinations),35 this study did not
demonstrate any imbalance in the incidence of pneumonia across treatment groups. However, this study was not
powered to have sufficient numbers or follow-up to detect
a meaningful difference in pneumonia events, and the low
event rate prevents any robust conclusions regarding any
differences between treatment arms for this adverse event.
In addition, the incidence of oral candidiasis was very low.
There were no significant demonstrable adverse effects on
the cardiovascular system, bone mineral density, lenticular
opacities, or intraocular pressure. Effects on hypothalamicpituitary-adrenal axis suppression were quite modest.
However, longer trials are needed to exclude any long-term
effects of treatment.
In this study, MF/F was delivered using a metered-dose
inhaler rather than a dry powder inhaler. This mode of
administration, in our opinion, offers some advantages.
Because a metered-dose inhaler requires a lower inspiratory
flow rate compared with a dry powder inhaler, the amount of
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medication deposited in the oral cavity and the glottic area
is reduced, which potentially accounts for the low incidence
of oral candidiasis and dysphonia demonstrated during
the study period. The generally finer particle sizes generated by metered-dose inhalers allow for greater lung and
peripheral lung deposition. Additionally, patients with
severe lung impairment may have difficulty generating
adequate inspiratory force to allow for effective use of
some dry powder inhalers. However, it is important for
patients to be adequately instructed on appropriate use
of both dry powder inhalers and metered-dose inhaler
devices. Both devices have been associated with a similar
percentage of errors.36
In conclusion, the results of this study show MF/F
400/10 µg twice daily to be an effective therapy for patients
with moderate to very severe COPD, based on improvements
in lung function and quality of life as well as reduction in
COPD exacerbations. Both MF/F 400/10 µg twice daily and
MF/F 200/10 µg twice daily were well tolerated.
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